Myfortic (Mycophenolic Acid)

Mycophenolic acid selectively inhibits the enzyme inosine monophosphate dehydrogenase (IMPDH), which is essential for the synthesis of guanosine nucleotides in lymphocytes. By limiting guanosine production, the drug suppresses the proliferation of T‑ and B‑lymphocytes, diminishing the immune system’s ability to attack transplanted tissue.

The dosage of Myfortic is individualized and must be determined by a qualified transplant physician or specialist. The prescribing clinician will consider factors such as the type of organ transplanted, the patient’s renal function, concomitant immunosuppressants, and laboratory monitoring results when setting the appropriate dose.

Myfortic is classified as pregnancy category D, indicating evidence of risk to the fetus. It should be avoided in pregnant women unless the potential benefit justifies the risk. Breastfeeding is not recommended while taking Myfortic because the drug can be excreted in milk and may affect the infant.

To place an order, submit an enquiry on the Myfortic product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any required temperature control), and necessary import documentation.

The primary alternative to Myfortic is CellCept (mycophenolate mofetil), which contains the same active moiety in a different salt form. Both agents inhibit IMPDH, but Myfortic’s delayed‑release formulation may offer improved gastrointestinal tolerability. Choice between them depends on physician preference, patient tolerance, and specific transplant protocols.

Myfortic tablets should be stored at ambient temperature, below 25 °C, in the original container to protect them from moisture and light. Keep the packaging tightly closed and out of reach of children. Do not store in a refrigerator or freezer.

Myfortic is taken orally as a delayed‑release tablet, usually with food to reduce gastrointestinal irritation. The tablet should be swallowed whole and not crushed, chewed, or split, as this could alter the release characteristics and affect drug absorption. Follow the prescribing clinician’s instructions regarding timing and dosing.

The most serious adverse events include severe infections such as sepsis or opportunistic pathogens, development of malignancies (especially lymphoproliferative disorders and skin cancers), and rare neurologic complications like progressive multifocal leukoencephalopathy. Regular monitoring of blood counts, organ function, and infection signs is essential to mitigate these risks.

Myfortic is contraindicated in patients with known hypersensitivity to mycophenolate sodium or any component of the tablet. It should also be avoided in individuals with active, uncontrolled infections, severe hepatic impairment, or in pregnant women unless the benefits outweigh the risks. A thorough medical assessment is required before initiating therapy.